RESTRICTED STOCK UNIT AGREEMENT UNDER THE AVANT IMMUNOTHERAPEUTICS, INC. 1999 STOCK OPTION AND INCENTIVE PLANRestricted Stock Unit Agreement • November 6th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
Pursuant to the AVANT Immunotherapeutics, Inc. 1999 Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, AVANT Immunotherapeutics, Inc. (the “Company”) hereby grants a deferred stock award consisting of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each “Restricted Stock Unit” shall relate to one share of Common Stock, par value $.001 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan.
SUBCONTRACT NO. DPSC03-02246Avant Immunotherapeutics Inc • November 6th, 2003 • In vitro & in vivo diagnostic substances
This is a Time and Materials (T&M) subcontract (hereinafter referred to as “Subcontract”) by and between DynPort Vaccine Company LLC (hereinafter referred to as “DVC”), a Virginia corporation, and AVANT Immunotherapeutics, Inc. (hereinafter referred to as “Subcontractor”), hereinafter referred to jointly as “the Parties”.
SUBCONTRACT MODIFICATION Page 1 of 1Avant Immunotherapeutics Inc • November 6th, 2003 • In vitro & in vivo diagnostic substances
SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • November 6th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
THIS SECOND AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (“Amendment”) by and between AVANT Immunotherapeutics, Inc., a Delaware corporation (f/k/a “T Cell Sciences, Inc.,” the “Company”) and Una S. Ryan, Ph.D. (the “Executive”), is dated as of September 18, 2003.
SUBCONTRACTOR SERVICE AGREEMENT NO. DPSC02-02257Subcontractor Service Agreement • November 6th, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
This is a Time and Materials (T&M) SUBCONTRACTOR SERVICE AGREEMENT (hereinafter referred to as “Agreement”) by and between DynPort Vaccine Company LLC (hereinafter referred to as “DVC”), a Virginia corporation, and AVANT Immunotherapeutics, Inc. (hereinafter referred to as “Subcontractor”), hereinafter referred to jointly as “the Parties”.
